Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma

  1. Gerard L Brien  Is a corresponding author
  2. David Remillard
  3. Junwei Shi
  4. Matthew L Hemming
  5. Jonathon Chabon
  6. Kieran Wynne
  7. Eugène T Dillon
  8. Gerard Cagney
  9. Guido Van Mierlo
  10. Marijke P Baltissen
  11. Michiel Vermeulen
  12. Jun Qi
  13. Stefan Fröhling
  14. Nathanael S Gray
  15. James E Bradner
  16. Christopher R Vakoc
  17. Scott A Armstrong  Is a corresponding author
  1. Dana Farber Cancer Institute, United States
  2. University of Pennsylvania, United States
  3. University College Dublin, Ireland
  4. Radboud Institute for Molecular Life Sciences, Radboud University Nijmegen, Netherlands
  5. Dana-Farber Cancer Institute, United States
  6. German Cancer Consortium (DKTK), Germany
  7. Cold Spring Harbor Laboratory, United States

Abstract

Synovial sarcoma tumours contain a characteristic fusion protein, SS18-SSX, which drives disease development. Targeting oncogenic fusion proteins presents an attractive therapeutic opportunity. However, SS18-SSX has proven intractable for therapeutic intervention. Using a domain-focused CRISPR screen we identified the bromodomain of BRD9 as a critical functional dependency in synovial sarcoma. BRD9 is a component of SS18-SSX containing BAF complexes in synovial sarcoma cells; and integration of BRD9 into these complexes is critical for cell growth. Moreover BRD9 and SS18-SSX co-localize extensively on the synovial sarcoma genome. Remarkably, synovial sarcoma cells are highly sensitive to a novel small molecule degrader of BRD9, while other sarcoma subtypes are unaffected. Degradation of BRD9 induces downregulation of oncogenic transcriptional programs and inhibits tumour progression in vivo. We demonstrate that BRD9 supports oncogenic mechanisms underlying the SS18-SSX fusion in synovial sarcoma and highlight targeted degradation of BRD9 as a potential therapeutic opportunity in this disease.

Data availability

All next-generation sequencing datasets generated in association with this work have been deposited in the Gene Expression Omnibus (GEO) under accession number GSE113229

The following data sets were generated

Article and author information

Author details

  1. Gerard L Brien

    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, United States
    For correspondence
    gbrien@tcd.ie
    Competing interests
    No competing interests declared.
  2. David Remillard

    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, United States
    Competing interests
    No competing interests declared.
  3. Junwei Shi

    Department of Cancer Biology, Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  4. Matthew L Hemming

    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, United States
    Competing interests
    No competing interests declared.
  5. Jonathon Chabon

    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, United States
    Competing interests
    No competing interests declared.
  6. Kieran Wynne

    School of Biomolecular and Biomedical Science, University College Dublin, Dublin, Ireland
    Competing interests
    No competing interests declared.
  7. Eugène T Dillon

    School of Biomolecular and Biomedical Science, University College Dublin, Dublin, Ireland
    Competing interests
    No competing interests declared.
  8. Gerard Cagney

    School of Biomolecular and Biomedical Science, University College Dublin, Dublin, Ireland
    Competing interests
    No competing interests declared.
  9. Guido Van Mierlo

    Department of Molecular Biology, Radboud Institute for Molecular Life Sciences, Radboud University Nijmegen, Nijmegen, Netherlands
    Competing interests
    No competing interests declared.
  10. Marijke P Baltissen

    Department of Molecular Biology, Radboud Institute for Molecular Life Sciences, Radboud University Nijmegen, Nijmegen, Netherlands
    Competing interests
    No competing interests declared.
  11. Michiel Vermeulen

    Department of Molecular Biology, Radboud Institute for Molecular Life Sciences, Radboud University Nijmegen, Nijmegen, Netherlands
    Competing interests
    No competing interests declared.
  12. Jun Qi

    Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    No competing interests declared.
  13. Stefan Fröhling

    German Cancer Consortium (DKTK), Heidelberg, Germany
    Competing interests
    No competing interests declared.
  14. Nathanael S Gray

    Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5354-7403
  15. James E Bradner

    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, United States
    Competing interests
    No competing interests declared.
  16. Christopher R Vakoc

    Cold Spring Harbor Laboratory, New York, United States
    Competing interests
    No competing interests declared.
  17. Scott A Armstrong

    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, United States
    For correspondence
    Scott_armstrong@dfci.harvard.edu
    Competing interests
    Scott A Armstrong, is a consultant and/or shareholder for Imago Biosciences, Cyteir Therapeutics, C4 Therapeutics, Syros Pharmaceuticals, OxStem Oncology, ProQR and Accent Therapeutics. Also receives research support from Janssen, Novartis, and AstraZeneca..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9099-4728

Funding

National Cancer Institute (CA176745)

  • Scott A Armstrong

Alex's Lemonade Stand Foundation for Childhood Cancer

  • Scott A Armstrong

European Molecular Biology Organization (ALTF-1235-2015)

  • Gerard L Brien

Irish Cancer Society (CRF18BRI)

  • Gerard L Brien

National Cancer Institute (CA066996)

  • Scott A Armstrong

National Cancer Institute (CA204915)

  • Scott A Armstrong

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All mouse experiments were performed according to approved institutional animal care and use committee (IACUC) protocols at the Dana Farber Cancer Institute.

Copyright

© 2018, Brien et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 9,891
    views
  • 1,713
    downloads
  • 145
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Gerard L Brien
  2. David Remillard
  3. Junwei Shi
  4. Matthew L Hemming
  5. Jonathon Chabon
  6. Kieran Wynne
  7. Eugène T Dillon
  8. Gerard Cagney
  9. Guido Van Mierlo
  10. Marijke P Baltissen
  11. Michiel Vermeulen
  12. Jun Qi
  13. Stefan Fröhling
  14. Nathanael S Gray
  15. James E Bradner
  16. Christopher R Vakoc
  17. Scott A Armstrong
(2018)
Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma
eLife 7:e41305.
https://doi.org/10.7554/eLife.41305

Share this article

https://doi.org/10.7554/eLife.41305

Further reading

    1. Biochemistry and Chemical Biology
    Parnian Arafi, Sujan Devkota ... Michael S Wolfe
    Research Article

    Missense mutations in the amyloid precursor protein (APP) and presenilin-1 (PSEN1) cause early-onset familial Alzheimer’s disease (FAD) and alter proteolytic production of secreted 38-to-43-residue amyloid β-peptides (Aβ) by the PSEN1-containing γ-secretase complex, ostensibly supporting the amyloid hypothesis of pathogenesis. However, proteolysis of APP substrate by γ-secretase is processive, involving initial endoproteolysis to produce long Aβ peptides of 48 or 49 residues followed by carboxypeptidase trimming in mostly tripeptide increments. We recently reported evidence that FAD mutations in APP and PSEN1 cause deficiencies in early steps in processive proteolysis of APP substrate C99 and that this results from stalled γ-secretase enzyme-substrate and/or enzyme-intermediate complexes. These stalled complexes triggered synaptic degeneration in a Caenorhabditis elegans model of FAD independently of Aβ production. Here, we conducted full quantitative analysis of all proteolytic events on APP substrate by γ-secretase with six additional PSEN1 FAD mutations and found that all six are deficient in multiple processing steps. However, only one of these (F386S) was deficient in certain trimming steps but not in endoproteolysis. Fluorescence lifetime imaging microscopy in intact cells revealed that all six PSEN1 FAD mutations lead to stalled γ-secretase enzyme-substrate/intermediate complexes. The F386S mutation, however, does so only in Aβ-rich regions of the cells, not in C99-rich regions, consistent with the deficiencies of this mutant enzyme only in trimming of Aβ intermediates. These findings provide further evidence that FAD mutations lead to stalled and stabilized γ-secretase enzyme-substrate and/or enzyme-intermediate complexes and are consistent with the stalled process rather than the products of γ-secretase proteolysis as the pathogenic trigger.

    1. Biochemistry and Chemical Biology
    2. Chromosomes and Gene Expression
    Kira A Cozzolino, Lynn Sanford ... Dylan J Taatjes
    Research Article

    Hyperactive interferon (IFN) signaling is a hallmark of Down syndrome (DS), a condition caused by Trisomy 21 (T21); strategies that normalize IFN signaling could benefit this population. Mediator-associated kinases CDK8 and CDK19 drive inflammatory responses through incompletely understood mechanisms. Using sibling-matched cell lines with/without T21, we investigated Mediator kinase function in the context of hyperactive IFN in DS over a 75 min to 24 hr timeframe. Activation of IFN-response genes was suppressed in cells treated with the CDK8/CDK19 inhibitor cortistatin A (CA), via rapid suppression of IFN-responsive transcription factor (TF) activity. We also discovered that CDK8/CDK19 affect splicing, a novel means by which Mediator kinases control gene expression. To further probe Mediator kinase function, we completed cytokine screens and metabolomics experiments. Cytokines are master regulators of inflammatory responses; by screening 105 different cytokine proteins, we show that Mediator kinases help drive IFN-dependent cytokine responses at least in part through transcriptional regulation of cytokine genes and receptors. Metabolomics revealed that Mediator kinase inhibition altered core metabolic pathways in cell type-specific ways, and broad upregulation of anti-inflammatory lipid mediators occurred specifically in kinase-inhibited cells during hyperactive IFNγ signaling. A subset of these lipids (e.g. oleamide, desmosterol) serve as ligands for nuclear receptors PPAR and LXR, and activation of these receptors occurred specifically during hyperactive IFN signaling in CA-treated cells, revealing mechanistic links between Mediator kinases, lipid metabolism, and nuclear receptor function. Collectively, our results establish CDK8/CDK19 as context-specific metabolic regulators, and reveal that these kinases control gene expression not only via TFs, but also through metabolic changes and splicing. Moreover, we establish that Mediator kinase inhibition antagonizes IFN signaling through transcriptional, metabolic, and cytokine responses, with implications for DS and other chronic inflammatory conditions.